Core Insights - GE HealthCare Technologies Inc. (GEHC) has received FDA 510(k) clearance for three new MRI innovations, which include SIGNA Sprint with Freelium, SIGNA Bolt, and SIGNA One, aimed at addressing challenges in the radiology market [1][2][4] Company Developments - The new SIGNA MRI systems are designed to enhance imaging access and efficiency, with a focus on reducing power consumption and helium reliance while improving image quality through AI tools [8][9][10] - SIGNA Sprint with Freelium is a 1.5T MRI platform that operates with less than 1% helium reliance, ensuring power efficiency and high imaging performance [9] - SIGNA Bolt, a next-generation 3T MRI system, features a deep-learning architecture that improves efficiency and sustainability, with 30% lower power consumption compared to previous models [10] - SIGNA One serves as the digital backbone of the MRI ecosystem, integrating AI-driven workflows to enhance efficiency and user experience [11] Market Position and Performance - Following the announcement of the new MRI systems, GEHC's shares increased by 0.1%, with a 12.3% rise over the past six months, contrasting with a 12.9% decline in the industry [3] - GEHC currently holds a market capitalization of $37.80 billion [6] Industry Trends - The magnetic resonance imaging market is projected to reach $8.8 billion by 2026, with a compound annual growth rate (CAGR) of 3.9% through 2035 [12] - Factors driving market growth include rising demand for advanced diagnostic imaging in neurology, oncology, and cardiology, as well as increased healthcare infrastructure investment [13] Additional Initiatives - GE HealthCare has expanded its contract with the Biomedical Advanced Research and Development Authority (BARDA) by $35 million to accelerate the development of AI-enabled ultrasound and imaging solutions [14] - The company has introduced ReadyFix, a remote fleet management platform aimed at improving medical device uptime and operational efficiency [15]

FDA Approves MRI TechnologyThe FDA has recently approved GE HealthCare’s next-generation SIGNA MRI technology, which is designed to enhance precision imaging and clinical efficiency. This milestone is significant as it includes the SIGNA Sprint with Freelium technology, aiming to reduce helium dependency—a critical advancement in making MRI technology more sustainable and cost-effective.The new SIGNA Bolt 3T MRI scanner, part of this FDA clearance, is noted for its powerful performance and sustainable desig ...

Core Insights - GE HealthCare Technologies Inc. (GEHC) has expanded its contract with the Biomedical Advanced Research and Development Authority (BARDA) by $35 million to enhance the development of AI-enabled ultrasound technologies and next-generation imaging platforms [1][2][5] Company Developments - The additional investment aims to accelerate the development of AI-enabled ultrasound tools for trauma assessment and improve readiness for large-scale casualty incidents [2][5] - GEHC's partnership with BARDA focuses on advancing ultrasound innovation through AI-powered tools and specialized hardware designed for frontline healthcare providers [3][5] - The expanded clinical scope of the agreement will support the development of multiple AI-enabled tools to enhance diagnostic workflows and reduce reliance on specialized operators, making them usable by non-expert ultrasound users [9][11] Market Position and Financial Performance - Following the announcement, GEHC shares increased by 1.6%, with a 11.6% rise over the past six months, contrasting with a 12.9% decline in the industry [4] - GEHC currently holds a market capitalization of $36.61 billion [7] Strategic Initiatives - The contract expansion is expected to strengthen GE HealthCare's position in the growing AI-enabled medical imaging market, enhancing its innovation pipeline and driving long-term revenue opportunities [5][12] - GEHC plans to advance point-of-care ultrasound systems that are reliable, portable, and easy to use in high-intensity environments [10] - The program also includes collaboration with clinicians to generate real-world evidence and guide product development, aiming to validate the clinical effectiveness of innovations [11] Industry Prospects - The AI in the ultrasound imaging market is projected to reach $1.22 billion by 2026, with a CAGR of 8.4% through 2035, driven by the recognition of AI-based technologies' benefits [13]

GE HealthCare Technologies Inc. (NASDAQ:GEHC) is one of the best medical technology stocks to invest in. On February 12, GE HealthCare Technologies Inc.’s (NASDAQ:GEHC) board declared a $0.035 per share cash dividend Q1 2026. The dividend will be disbursed on May 15, 2026, to shareholders of record as of April 3, 2026. This dividend amount is unchanged since Q4 2025. GE HealthCare Technologies Inc. (GEHC) Expands Healthcare Technology Offerings Meanwhile, GE HealthCare announced the US launch of ReadyFix ...

href="https://www.businesswire.com/news/home/20260212605971/en/GE-HealthCare-announces-cash- dividend-for-first-quarter-of-2026"English] (https://www.businesswire.com/news/home/20260212605971/en/GE-HealthCare-announces-cash-dividend-for- first-quarter-of-2026)---### ContactsInvestor Relations Contact: Carolynne Borders +1 631 662 4317 [carolynne.borders@gehealthcare.com]Media Contact: Jennifer Fox + 1 414 530 3027 [jennifer.r.fox@gehealthcare.com]More News From GE HealthCare Technologies Inc.Get RSS Feed## ...

href="https://www.businesswire.com/news/home/20260212907092/en/GE-HealthCare-management-to-present- at-upcoming-investor-conferences"English] (https://www.businesswire.com/news/home/20260212907092/en/GE-HealthCare-management-to-present-at- upcoming-investor-conferences)---### ContactsGE HealthCare Investor Contact: Carolynne Borders (631) 662- 4317 [Carolynne.borders@gehealthcare.com]GE HealthCare Media Contact: Jennifer Fox (414) 530-3027 [Jennifer.r.fox@gehealthcare.com]More News From GE HealthCare Techno ...

Core Viewpoint - GE HealthCare Technologies (GEHC) is currently viewed as a more attractive investment option compared to Stryker (SYK) for value investors, based on stronger earnings outlook and favorable valuation metrics [3][7]. Valuation Metrics - GEHC has a forward P/E ratio of 15.89, significantly lower than SYK's forward P/E of 24.22, indicating that GEHC may be undervalued [5]. - The PEG ratio for GEHC is 1.75, while SYK's PEG ratio stands at 2.11, suggesting that GEHC offers better value relative to its expected earnings growth [5]. - GEHC's P/B ratio is 3.47, compared to SYK's P/B of 6.16, further supporting the notion that GEHC is more attractively priced [6]. Investment Ratings - GEHC holds a Zacks Rank of 2 (Buy), indicating a positive earnings estimate revision trend, while SYK has a Zacks Rank of 3 (Hold) [3]. - Based on the overall valuation metrics, GEHC has a Value grade of A, whereas SYK has a Value grade of C, reinforcing the preference for GEHC among value investors [6].

Core Insights - GE HealthCare Technologies Inc. (GEHC) has launched ReadyFix, a remote fleet management solution designed to enhance medical device uptime and operational efficiency in healthcare systems [1][8] - The solution integrates with MAC VU360 ECG workstations, providing high-quality ECG measurements and real-time data access for remote diagnostics and maintenance [1][4] Product Launch and Features - ReadyFix aims to simplify maintenance and operations of connected medical devices, allowing healthcare teams to focus on cardiac patient care [2][4] - The platform supports centralized management of device complexity, enabling standardized clinical configurations and facilitating proactive maintenance through real-time diagnostics [9][10] Market Context and Trends - The fleet management market is projected to reach $32.29 billion by 2026, with a CAGR of 10% through 2035, driven by the growth of connected medical devices and operational efficiency needs [13] - The increasing complexity of device management is highlighted by the fact that hospitals may have 10 to 15 connected devices per bed, leading to higher maintenance demands [10][11] Financial Performance and Stock Movement - Following the ReadyFix announcement, GEHC shares fell by 1.9%, although the company has seen an 8.3% increase over the past six months, contrasting with an 11.3% decline in the industry [3] - GEHC currently holds a market capitalization of $36.76 billion [6] Workforce Challenges - A significant portion of biomedical engineers report heavy workloads, with projections indicating over 7,300 annual job openings for biomedical equipment technicians in the next decade, while only about 400 graduates are produced annually [11] - ReadyFix is positioned to help hospitals maintain high reliability standards despite workforce constraints [11][12]

Core Viewpoint - GE HealthCare Technologies Inc. (NASDAQ:GEHC) is currently considered one of the best IPO stocks to buy, with multiple analysts raising their price targets following strong Q4 2025 results and an optimistic outlook for 2026 [1][2][3]. Analyst Ratings and Price Targets - Barclays increased its price target for GE HealthCare to $87 from $86, maintaining an Equal Weight rating, citing a solid Q4 2025 performance and a 2026 outlook that exceeds market expectations [1]. - Stifel analyst Rick Wise raised the price target to $98 from $95 with a Buy rating, expressing encouragement regarding the company's prudent outlook for 2026 following the earnings call [2]. - Morgan Stanley also raised its price target for GE HealthCare to $85 from $80, maintaining an Equal Weight rating, and updated its risk-reward assessment based on Q4 2025 results that surpassed expectations [3]. Company Overview - GE HealthCare Technologies Inc. develops, manufactures, and markets products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the US, Canada, and internationally [4].

Core Insights - GE HealthCare Technologies Inc. (GEHC) has announced a collaboration with Diagnoly to integrate AI-powered fetal screening into its Voluson women's health ultrasound systems, enhancing its portfolio of clinical AI tools [1][4] - The partnership aims to improve real-time cardiac and brain analysis during fetal exams, thereby increasing the utility of existing ultrasound hardware and pushing ultrasound further into high-value, outcomes-focused care [9][10] Company Strategy - GEHC's strategy focuses on embedding high-value AI applications into its installed base to enhance system differentiation and drive software-led growth [2][4] - By expanding the Voluson Solution Store with FDA-cleared, CE-marked AI offerings, GEHC aims to deepen customer engagement and improve precision in prenatal care [2][4] Market Performance - Following the announcement, GEHC shares traded flat in after-market trading, with a 10.4% gain over the past six months, compared to an 11.3% decline in the industry and an 11% rise in the S&P 500 [3] - GEHC currently has a market capitalization of $36.76 billion [6] Long-term Outlook - The collaboration with Diagnoly strengthens GEHC's transition toward a software- and AI-led growth model, enhancing the value of its large installed ultrasound base [4] - Integrating FDA-cleared AI tools into Voluson systems is expected to improve product differentiation, support premium pricing, and increase customer retention [4][10] Industry Prospects - The global fetal monitoring market is projected to grow from $5.66 billion in 2024 to approximately $10.81 billion by 2034, with a compound annual growth rate (CAGR) of 6.68% [12] - Key drivers of market growth include the rising prevalence of chronic conditions, growing adoption of minimally invasive treatments, rapid advances in imaging technologies, and a stronger focus on early disease detection [13]